The Incidence and Management of Cancer-Related Anorexia During Treatment with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors.

"Disclosure Although authors received payment for advisory board services, this present manuscript was prepared independently with funding for medical writing only. Shunji Takahashi has received medical writing support from Eisai Co., Ltd.; grants or contracts from MSD K.K., Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., AstraZeneca K.K., Bristol-Myers Squibb K.K., Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., Novartis Pharma K.K., Taiho Pharmaceutical Co., Ltd., and Daiichi Sankyo, Co., Ltd.; and payments or honoraria from Eisai Co., Ltd., Novartis Pharma K.K., Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., MSD K.K., Taiho Pharmaceutical Co., Ltd., Bayer Ltd., and Bristol-Myers Squibb K.K. Koji Matsumoto has received medical writing support from Eisai Co., Ltd.; payments or honoraria from Eisai Co., Ltd., Kyowa Kirin Co., Ltd., MSD K.K., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Bristol-Myers Squibb K.K., ACTmed Co., Ltd., Bayer Yakuhin Ltd., Ono Pharmaceutical Co., Ltd., and Kaken Pharmaceutical Co., Ltd.; and participated on a data safety monitoring board or advisory board for Eisai Co., Ltd, AstraZeneca K.K., MSD K.K., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., and Genmab K.K. Kojiro Ohba, Yasuhiro Nakano, Yasushi Miyazawa, and Takumi Kawaguchi have received payment or honoraria from Eisai Co., Ltd., and medical writing support for the present manuscript. Yasushi Miyazawa has received consulting fees from AIM Services Co., Ltd., Forico Foods Co., Ltd., and TOP Corporation; payment or honoraria from Nestlé Health Science Co., Ltd. and Otsuka Pharmaceutical Factory, Inc.; and has a leadership or fiduciary role in The Japan Association for Nutritional Management Practice. Takumi Kawaguchi has received consulting fees from ASKA Pharmaceutical Co., Ltd., Kowa Co., Ltd., and Taisho Pharmaceutical Co., Ltd.; received payment or honoraria from ASKA Pharmaceutical Co., Ltd., AstraZeneca K.K., AbbVie GK., Chugai Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., Gilead Sciences, Inc., Janssen Pharmaceutical K.K., KM Biologics, Kowa Company, Ltd., Merck & Co., Inc., Miyarisan Pharmaceutical Co., Ltd., Nobelpharma Co., Ltd., Novartis AG., Otsuka Pharmaceutical Factory, Inc., Otsuka Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., SMC Laboratories, Inc., and Taisho Pharmaceutical Co., Ltd.; and has received medical writing support from Eisai Co., Ltd. The authors report no other conflicts of interest in this work."

"The authors wish to thank Hannah Read, PhD, of Edanz (www.edanz.com) for providing medical writing support, which was funded by Eisai Co., Ltd., in accordance with the 2022 Good Publication Practice guidelines (https://www.ismpp.org/gpp-2022). We acknowledge Mr. Hiromasa Sasaki and Dr. Michiko Sugawara (Eisai Co., Ltd.) for their support as publication coordinators."